STAT3 and multiple sclerosis: Thus, in an earlier study it was reported that FTY720, an antagonist of S1PR signaling that is already approved for the treatment of patients with multiple sclerosis, can inhibit S1PR1 expression, downregulate STAT3 activity, and inhibit the growth of DLBCL cells both in vitro and in vivo [41,80].